Johnson & Johnson Annual Shareholders Meeting Summary

Edited Brief of JNJ.N shareholder or annual meeting 24-Apr-25 2:00pm GMT

...A. Operational sales growth was 7% and adjusted net earnings were $24.2 billion. B. We continued to execute against our capital allocation priorities and generated a notable increase in our free cash flow to approximately $20 billion. C. As announced recently, our progress enabled us to increase our dividend for a 63rd consecutive year which we know is important for Johnson & Johnson shareholders. D. Fueled by a strong balance sheet, we have deployed and committed approximately $50 billion in R&D and other inorganic growth opportunities since January 2024. E. Major acquisitions included Shockwave and V-Wave in medtech, and Ambrx Proteologix, and the NM26 by specific antibody in innovative medicine, as well as the acquisition of intracellular therapies announced in January this year. F. And with more than 40 (technical difficulty) manufacturing R&D and technology investments of more than $55 billion in the United States over the next four years. G. This represents a 25% increase in investment...

Brief